India Launches World‑First Clinical Study Evaluating Ayurveda as Adjunct to TB Treatment – Dr Jitendra Singh — UPSC Current Affairs | March 24, 2026
India Launches World‑First Clinical Study Evaluating Ayurveda as Adjunct to TB Treatment – Dr Jitendra Singh
On World Tuberculosis Day, India announced a pioneering global clinical trial that will scientifically assess Ayurveda as an adjunct to standard anti‑tuberculosis treatment. Spearheaded by Union Minister <strong>Dr Jitendra Singh</strong>, the study involves 1,250 patients across eight centres, reflecting a ‘whole‑of‑science, whole‑of‑government, whole‑of‑nation’ approach to accelerate TB elimination and generate evidence for integrative healthcare.
India’s First Global Clinical Study on Ayurveda‑Adjunct TB Treatment On World Tuberculosis Day 2026, the Union Minister of State (Independent Charge) for Science & Technology, Dr Jitendra Singh , announced a landmark clinical trial that will, for the first time globally, evaluate Ayurveda as an adjunct to standard ATT . The study aims to improve patient outcomes, nutrition, and quality of life while generating scientific evidence for integrative care. Key Developments Collaboration between the DBT and the Ministry of Ayush. Enrollment of 1,250 newly diagnosed TB patients across eight premier institutions. Evaluation parameters: body weight, nutritional status, disease progression, quality of life, safety and tolerability. Use of advanced tools – DEXA, MRI, immune profiling, metabolomics, and single‑cell RNA sequencing – to study TB‑associated cachexia. Integration with existing programmes such as the NTEP and the RePORT India network. Important Facts India accounts for roughly 25 % of the global TB burden . The incidence fell to 187 cases per 100,000 population in 2024 , a 21 % decline since 2015, reflecting the impact of intensified diagnostics, digital adherence technologies, and patient‑centric care under NTEP. However, challenges persist: drug‑related toxicity, undernutrition, immune suppression, post‑cure pulmonary impairment, and the rising threat of drug‑resistant TB . The study also builds on the 32,000 Mycobacterium tuberculosis strains to inform drug discovery and resistance monitoring (GS3: Health)">InTGS Consortium , which has created a national genomic repository to support diagnostics and containment strategies. UPSC Relevance Understanding this initiative touches multiple UPSC syllabus areas: Health sector reforms (GS3) , the role of traditional knowledge systems in modern policy (GS4) , and the importance of inter‑ministerial coordination (GS2: Polity) . The case exemplifies how scientific validation of indigenous systems can be leveraged for public health, a recurring theme in ethics and governance questions. Way Forward The Ministry urges a ‘whole‑of‑nation’ effort: community awareness to reduce stigma, nutritional support, and lifestyle interventions alongside drug therapy. Successful outcomes could lead to policy incorporation of Ayurveda‑based supportive care in the NTEP, set a precedent for integrative research, and strengthen India’s position as a global leader in TB elimination.
Login to bookmark articles
Login to mark articles as complete
Overview
Ayurveda‑Adjunct TB Trial Marks India's Push for Integrative Health in TB Elimination
Key Facts
World Tuberculosis Day, 24 March 2026, saw launch of the world‑first clinical trial evaluating Ayurveda as adjunct to standard ATT.
The trial will enroll 1,250 newly diagnosed TB patients across eight premier institutions under a DBT‑Ayush collaboration.
Evaluation parameters include body weight, nutritional status, disease progression, quality of life, safety and tolerability, using DEXA, MRI, immune profiling, metabolomics and single‑cell RNA sequencing.
The study is integrated with the National TB Elimination Programme (NTEP) and the RePORT India network, and builds on the InTGS genomic surveillance initiative.
India contributes roughly 25% of the global TB burden; incidence fell to 187 cases per 100,000 population in 2024, a 21% decline since 2015.
The trial aims to generate scientific evidence for incorporating Ayurveda‑based supportive care into the TB Mukt Bharat mission.
It addresses persistent challenges such as drug‑related toxicity, undernutrition, immune suppression, post‑cure pulmonary impairment and drug‑resistant TB.
Background & Context
The initiative aligns with GS3 health sector reforms by seeking to improve TB treatment outcomes through integrative care, while also reflecting GS4's focus on leveraging traditional knowledge systems. It exemplifies inter‑ministerial coordination (DBT, Ministry of Ayush, Ministry of Health) – a key aspect of governance and policy implementation in the UPSC syllabus.
UPSC Syllabus Connections
GS3•Developments in science and technology and their applicationsPrelims_GS•Biology and HealthGS2•Government policies and interventions for developmentEssay•Youth, Health and WelfareEssay•Science, Technology and SocietyEssay•Education, Knowledge and CulturePrelims_GS•National Current AffairsGS2•Functions and responsibilities of Union and StatesPrelims_GS•Public Policy and Rights IssuesEssay•Economy, Development and Inequality
Mains Answer Angle
In GS3 (Health) or GS4 (Traditional Knowledge) answers, discuss how scientific validation of Ayurveda can strengthen TB Mukt Bharat, citing the trial’s design, expected benefits and policy implications.